A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
Completed · Phase 1 · NCT07141199
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $1,210
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 24
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-8736 (drug), Placebo (drug)
- Dates
- Started 2025-09-02; completion 2026-03-23
- Results posted
- Not yet
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.
From ClinicalTrials.gov, last updated 2026-04-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1,210 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $1,210
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.